Name | R1530 |
Synonyms | R1530 R-1521 R 1530 R-1530 R-1530 CS-1111 5-(2-Chlorophenyl)-7-fluoro-1,2-dihydro-8-methoxy-3-methylpyrazolo[3,4-b][1,4]benzodiazepine |
CAS | 882531-87-5 |
Molecular Formula | C18H14ClFN4O |
Molar Mass | 356.78 |
Density | 1.46±0.1 g/cm3(Predicted) |
Boling Point | 550.9±50.0 °C(Predicted) |
Solubility | DMSO: soluble20mg/mL, clear |
Appearance | powder |
Color | , white to yellow to light brown |
pKa | 17.23±0.40(Predicted) |
Storage Condition | 2-8°C |
Use | R1530 is a multiplex kinase inhibitor with anti-angiogenic and anti-tumor activity. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.803 ml | 14.014 ml | 28.028 ml |
5 mM | 0.561 ml | 2.803 ml | 5.606 ml |
10 mM | 0.28 ml | 1.401 ml | 2.803 ml |
5 mM | 0.056 ml | 0.28 ml | 0.561 ml |
biological activity | R1530 is a highly effective, orally active mitotic/angiogenic (mitosis/angiogenesis) dual-action inhibitor with anti-tumor and anti-angiogenic activity. R1530 is a multi-kinase inhibitor, and the Kd bound to 31 kinases is less than 500 nM. The IC50 of R1530 inhibiting the effects of VGFR2 and FGFR1 was 10 nM and 28 nM, respectively. |
target | KDR 10 nM (IC 50 ) FGFR1 28 nM (IC 50 ) |